Literature DB >> 9461093

In situ complement activation in porcine membranoproliferative glomerulonephritis type II.

J H Jansen1, K Høgåsen, M Harboe, T Hovig.   

Abstract

Pigs genetically deficient in complement factor H all develop lethal membranoproliferative glomerulonephritis (MPGN) type II characterized by massive glomerular deposits of complement, intramembranous dense deposits, and mesangial hypercellularity. To elucidate the chronological relationship between these glomerular changes, and to precisely determine the localization of glomerular complement deposits, we studied kidney specimens from factor H-deficient piglets at different ages from fetal life until terminal kidney failure had developed. Deposits of C3 and the terminal complement complex localized within the glomerular basement membrane (GBM) were present already in factor H-deficient fetuses, without concurrent intramembranous dense deposits or mesangial hypercellularity. Incipient subendothelial dense deposits containing complement appeared no earlier than four days after birth, and intramembranous dense deposits in older piglets with established MPGN type II also contained large amounts of complement as detected by immune electron microscopy. Onset of kidney failure coincided with pronounced mesangial hypercellularity and expansion, compromising glomerular capillary patency. Formation of glomerular capillary wall double contours coincided with electron microscopic evidence of laminar disintegration of intramembranous dense deposits. Complement was also deposited in the mesangial matrix, but not on glomerular cells. We conclude that all components of the alternative and terminal pathways of complement have access into the GBM and the mesangial matrix. In the absence of factor H, complement is spontaneously activated and deposited in situ in these locations resulting in dense deposit formation. It is proposed that factor H dysfunction may play an essential role even in human MPGN type II.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9461093     DOI: 10.1046/j.1523-1755.1998.00765.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  18 in total

1.  Evidence for an inflammatory process in age-related macular degeneration gains new support.

Authors:  Dean Bok
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-10       Impact factor: 11.205

Review 2.  C3 Glomerulopathy.

Authors:  Magdalena Riedl; Paul Thorner; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2016-04-07       Impact factor: 3.714

3.  Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease).

Authors:  M A Abrera-Abeleda; C Nishimura; J L H Smith; S Sethi; J L McRae; B F Murphy; G Silvestri; C Skerka; M Józsi; P F Zipfel; G S Hageman; R J H Smith
Journal:  J Med Genet       Date:  2005-11-18       Impact factor: 6.318

4.  Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice.

Authors:  Fadi Fakhouri; Elena Goicoechea de Jorge; Frédérique Brune; Philippe Azam; H Terence Cook; Matthew C Pickering
Journal:  Kidney Int       Date:  2010-05-05       Impact factor: 10.612

Review 5.  Genetic kidney diseases in the pediatric population of southern Israel.

Authors:  Gal Finer; Hanna Shalev; Daniel Landau
Journal:  Pediatr Nephrol       Date:  2006-05-30       Impact factor: 3.714

6.  Cryoglobulinemic glomerulonephritis in thymic stromal lymphopoietin transgenic mice.

Authors:  S Taneda; S Segerer; K L Hudkins; Y Cui; M Wen; M Segerer; M H Wener; C G Khairallah; A G Farr; C E Alpers
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

Review 7.  Dense deposit disease.

Authors:  Richard J H Smith; Claire L Harris; Matthew C Pickering
Journal:  Mol Immunol       Date:  2011-05-24       Impact factor: 4.407

Review 8.  Translational mini-review series on complement factor H: therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis.

Authors:  M Noris; G Remuzzi
Journal:  Clin Exp Immunol       Date:  2007-12-07       Impact factor: 4.330

Review 9.  Membranoproliferative glomerulonephritis.

Authors:  Bassam Alchi; David Jayne
Journal:  Pediatr Nephrol       Date:  2009-11-12       Impact factor: 3.714

10.  Novel targets for immunotherapy in glomerulonephritis.

Authors:  Mary H Foster
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.